Todas as matérias desta seção, das mais recentes às mais antigas — página 239 de 371.
Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
USA Rare Earth (NASDAQ:USAR) reported a transformative shift in its financial position and operational footprint for the full year 2025, underpinned by a massive capital injection that establishes the company as a primary contender in the race to build a non-Chinese permanent magnet supply chain.
Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.
Boardwalk Pipelines (NYSE:SR) announced today that it has entered into a definitive agreement to acquire Spire Marketing from Spire.
United Therapeutics (NASDAQ:UTHR), a public benefit corporation, today announced that its pivotal TETON-1 study evaluating nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.
Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biotechnology company pioneering precision medicines for brain diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
GSK (NYSE:GSK) today announced that China’s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype.
Sysco (NYSE:SYY), North America’s largest foodservice distributor, announced an agreement to acquire Jetro Restaurant Depot, a leading cash-and-carry wholesaler serving independent restaurants and foodservice operators, for approximately $29.1 billion in a combination of cash and stock.
Zymeworks (NASDAQ:ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191 for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).
Leidos (NYSE:LDOS), a Fortune 500 innovation leader in defense, aviation, and information technology, announced today the successful completion of its acquisition of ENTRUST Solutions Group for approximately $2.4 billion.
IDEAYA Biosciences (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the first-patient-in (FPI) for its Phase 1 clinical trial evaluating the combination of IDE849 and IDE161.
NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches, today announced promising initial data from the Phase 2 CONVERGE study evaluating its lead candidate, JNJ-1900 (NBTXR3), in patients with stage 3 inoperable non-small cell lung cancer (NSCLC).
Bitdeer Technologies Group (NASDAQ:BTDR), a global leader in advanced computing and blockchain infrastructure, announced today that its subsidiary, Tydal Data Center AS (TDC), has officially engaged Data Center Installations AS (DCI) to develop a state-of-the-art 180 MW artificial intelligence data center in Tydal, Norway.
Palantir Technologies (NASDAQ:PLTR) today announced a five-year renewal and expansion of its strategic partnership with Stellantis (NYSE:STLA).
Rio Tinto Group (NYSE:RIO), the world’s leading iron ore producer, announced Monday that it has resumed ship loading at the majority of its Pilbara port terminals following a temporary suspension caused by Tropical Cyclone Narelle.
Rio Tinto (ASX:RIO) has initiated legal proceedings against the United States, seeking a refund of millions in tariffs following a landmark Supreme Court ruling.
Rocket Pharmaceuticals (NASDAQ:RCKT), a leading biotechnology firm specializing in genetic therapies for rare disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel).
enVVeno Medical (NASDAQ:NVNO), a clinical-stage medical device company developing innovative solutions for the treatment of chronic venous insufficiency (CVI), today reported its financial results for the full year ended December 31, 2025.
United-Guardian (NASDAQ:UG), a diversified manufacturer of pharmaceutical, cosmetic, and healthcare products, today reported its financial results for the full year ended December 31, 2025.
Carnival (NYSE:CCL), the world’s largest leisure travel company, today reported record-breaking financial results for the first quarter of 2026, signaling a robust start to the fiscal year.
Adagio Medical Holdings (NASDAQ:ADGM), a specialist in catheter ablation technologies for cardiac arrhythmias, reported a substantial narrowing of its net loss for the fiscal year ended Dec. 31, 2025, as the company realized the benefits of an aggressive cost-reduction strategy and a streamlined corporate profile.
Hydrofarm Holdings Group (NASDAQ:HYFM), a leading independent distributor and manufacturer of controlled environment agriculture (CEA) equipment and supplies, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
TMC the metals company (NASDAQ:TMC), a company focused on collecting polymetallic nodules from the deep seabed to supply critical battery metals, reported its fourth-quarter and full-year 2025 financial results along with a corporate update on March 27, 2026.
Werewolf Therapeutics (NASDAQ:HOWL), an innovative biopharmaceutical company developing "inducible" cytokines to treat cancer, today announced it has initiated a formal process to explore strategic alternatives.
